← All indications
Leukemia, Promyelocytic, Acute
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.
Drugs by status
Approved for this indication (2)
Phase 4 trials (7)
Phase 3 trials (5)
Phase 1 trials (12)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (11)
Organization Involved with Phase 3 Indications (23)
- Pfizer
- Wyeth
- Teva
- National Cancer Institute (NCI)
- University of Roma La Sapienza
- Associazione Italiana Ematologia Oncologia Pediatrica
- Cancer and Leukemia Group B (CALGB)
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Radboud University
- Southwest Oncology Group
- Stanford University
- University of Rome Tor Vergata
- Groupe d'etude et de travail sur les leucemies aigues promyelocytaires
- Groupe Francophone des Myelodysplasies
- University of Lille
- European Organisation for Research and Treatment of Cancer
- Government of China
- University of Paris
- German Federal Ministry of Education and Research
- Haemato Oncology Foundation for Adults in the Netherlands
- Government of India
- People's Liberation Army of China
- Christian Medical College, Vellore, India
Organization Involved with Phase 2 Indications (24)
- Cephalon
- Astellas
- NuRx Pharmaceuticals, Inc.
- CytRx
- National Heart, Lung, and Blood Institute (NHLBI)
- Case Western Reserve University
- Cornell University
- ECOG-ACRIN Cancer Research Group
- University of Washington
- Johns Hopkins University
- Northwestern University
- University of Heidelberg
- University of New Mexico
- University of South Florida
- University of Southern California
- University of Toronto
- Wake Forest University
- Mayo Clinic
- University of Chicago
- The University of Hong Kong
- City of Hope National Medical Center
- University of Texas at Houston
- Washington University in St. Louis
- New York Presbyterian Hospital
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (1)